Citri made successful development of Clarithromycin
Published: 2001-12-20 06:56:00
Updated: 2001-12-20 06:56:00
Citri Co. announced on Dec. 14 that Clarithromycin, an anti-bacterial agent against Helicobacter pylori was successfully developed for the lst time in Korea and the 2nd in the world after Abbott. Its patent registration was also completed.
Citri has put 890 million won of R&D investment for 4 ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
